Sarepta Therapeutics draws renewed market attention following brokerage target revisions and institutional portfolio ...

Sarepta Therapeutics receives a revised brokerage price outlook, drawing market attention toward the rare disease biotechnology segment. Institutional capital repositioning across biotechnology ...

Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified ...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing ...

Exposure to wildfire smoke can more than double the risk of respiratory failure or death for ALS patients, a study found.

In a strikingly blunt briefing, a senior FDA official accused uniQure of pushing “distorted” data to mask a “failed” therapy ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...

In this article, we will discuss the 13 Best Hot Stocks to Buy According to Analysts. On March 6, Dan Niles, Niles Investment Management founder, joined ‘Power Lunch’ on CNBC to discuss the broader ...

Detailed price information for Atrium Therapeutics Inc (RNA-Q) from The Globe and Mail including charting and trades.

Louise James often asks herself how she has lived 10 years without her loved ones, but says she has found strength in the many signs they have given her to show they are near.

Brooklyn Nets radio play-by-play voice Chris Carrino Sr. was honored by the Naismith Basketball Hall of Fame with a Curt Gowdy Media Award.

More than 30 rare muscular dystrophy types cause progressive muscle weakness from inherited gene mutations. Combined, they affect about 1 in 5,000 to 8,000 people. Common subtypes vary by age of onset ...